Ideaya Biosciences

GSK pumps $120M into partnership with Ideaya in oncology precision medicine play

The California-based company is developing drugs that work through "synthetic lethality," whereby they target two genes at once rather than only targeting one.

By Alaric DeArment

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

A Personalized Approach to Medication Nonadherence

At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.